Subtype
Virus-Related Malignant Neoplasm
CI-CAN-00001652Explore in graph →
132 active trials4 approved drugs1 evidence items
- NCIt
- C27673
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001652Explore in graph →
Clinical trials
537 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (75)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04301076 | Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07565740 | Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04902443 | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05985681 | Testing RG1-VLP Vaccine to Prevent HPV-related Cancers | recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06016920 | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 110 | Nykode Therapeutics ASAINDUSTRY | 7 | Aug 26, 2026 | clinicaltrials |
| NCT04941274 | Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04303117 | PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05077527 | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 20 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06797986 | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. | recruiting | Phase 1 / Phase 2 | 37 | Cellid Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06741072 | BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants | recruiting | Phase 1 | 55 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04664179 | EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma(CILESTE) | recruiting | Phase 1 | 52 | Baylor College of MedicineOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07075328 | A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Otsuka Medical Devices Co., Ltd. JapanINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06544265 | SynKIR-310 for Relapsed/Refractory B-NHL | recruiting | Phase 1 | 36 | Verismo TherapeuticsINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
| NCT04848064 | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | recruiting | Phase 1 | 12 | John ReneauOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06343311 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(STARLIGHT-1) | recruiting | Phase 1 / Phase 2 | 21 | Estrella Biopharma, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT05829629 | Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women | recruiting | Phase 1 | 20 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06617000 | A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | recruiting | Phase 1 | 38 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials